Associate Professor, Internal Medicine, University of Iowa College of Medicine
Rheumatology
Dr. Petar S. Lenert, MD
|
|
Give Review
Doctor Petar S. Lenert, MD is an expert in the field of Rheumatology. He received awards:"CMS Meaningful Use Stage 1 Certification". Petar S. Lenert, MD has written publications. He has 53 publications published with PubMed. The lastest publication is: '[Psoriatic arthritis: case report of acute HLA-B27 positive polyarthritis preceding the onset of typical skin changes].' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Interfering with baffled B Cells at the lupus tollway: Promises, successes, and failed expectations.
- ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: case-based review.
- Aggregation and secondary loop structure of oligonucleotides do not determine their ability to inhibit TLR9.
- Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.
- Influence of Bence-Jones proteins, hyperviscosity, hypercalcemia, hyperuricemia and dehydration on development of renal changes in plasma Cell dyscrasias.
- Suppression of experimental allergic thyroiditis in rats treated with lithium chloride.
- [Chronic urticaria from the aspect of autoimmune Diseases].
- [Immunologic characterization of autoreactivity to nuclear antigens in patients with systemic Lupus erythematosus].
- Synthetic peptides of human CD4 enhance binding of immunoglobulins to monocyte/macrophage Cells. II. Mechanisms of enhancement.
- Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
- Human recombinant CD4 and CD4-derived synthetic peptides agglutinate immunoglobulin-coated latex particles. Evidence that residues 25-28 and 35-38 of human CD4 form tw...
- [Systemic Diseases: evaluation of important laboratory parameters in 3 cases with unusual skin changes].
- CD4-reactive antibodies in systemic Lupus erythematosus.
- Human CD4-reactive antibodies from SLE patients induce reversible inhibition of polyclonal T lymphocyte proliferation.
- [Results of a multi-year study of persons with transplanted kidneys].
- [Clinical and morphologic features in patients with acute nephritis Syndrome].
- [Methylprednisolone pulse therapy in the early phases of Lupus nephritis].
- Ig VH-dependent interaction between immunoglobulins and CD4.
- [Psoriatic Arthritis: case report of acute HLA-B27 positive polyArthritis preceding the onset of typical skin changes].
- [Anti-U1RNP antibodies and Lupus nephritis].
- Identification of methylated CpG motifs as inhibitors of the Immune stimulatory CpG motifs.
- CpG stimulation of primary mouse B Cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation.
- Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B Cells.
- Innate Immune responses in lupus-prone Palmerston North mice: differential responses to LPS and bacterial DNA/CpG oligonucleotides.
- Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B Cells.
- Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and NK-Cell lytic activity in mouse spleen Cells.
- Activation of marginal zone B Cells from lupus mice with type A(D) CpG-oligodeoxynucleotides.
- TLR-9 activation of marginal zone B Cells in lupus mice regulates immunity through increased IL-10 production.
- Sequence requirements for oligodeoxyribonucleotide inhibitory activity.
- FcγRIIB regulation of BCR/TLR-dependent autoreactive B-Cell responses.
- B Cells do not take up bacterial DNA: an essential role for antigen in exposure of DNA to toll-like receptor-9.
- Extended sequence preferences for oligodeoxyribonucleotide activity.
- TLR9-independent activation of B lymphocytes by bacterial DNA.
- Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B Cells in lupus mice.
- Structural requirements and applications of inhibitory oligodeoxyribonucleotides.
- DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-Cell and dendritic Cell activation in vitro and autoantibody product...
- Optimal oligonucleotide sequences for TLR9 inhibitory activity in human Cells: lack of correlation with TLR9 binding.
- Modulating toll-like receptor 7 and 9 Responses as therapy for allergy and autoimmunity.
- Targeting Toll-like receptor signaling in plasmacytoid dendritic Cells and autoreactive B Cells as a therapy for lupus.
- Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune Diseases?
- Nucleic acid sensing receptors in systemic Lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating Lupus.
- Engagement of the B Cell receptor for antigen differentially affects B Cell responses to Toll-like receptor-7 agonists and antagonists in BXSB mice.
- B-Cell receptor for antigen modulates B-Cell responses to complex TLR9 agonists and antagonists: implications for systemic lupus erythematosus.
- [Prophylaxis and therapy of infections in allogenic bone marrow transplantation in patients with hematologic Diseases].
- Synthetic peptides of human CD4 enhance binding of Ig to monocyte/macrophage Cells. I. Characterization and mapping studies.
- CD4/immunoglobulin interaction: implications for Immune physiology and autoimmunity.
- Human CD4 binds immunoglobulins.
- [Dynamic radionuclide study of the transplanted kidney supplemented by determination of a perfusion index].
- [The significance of dysmorphic erythrocytes in urinary sediment in differentiating glomerular from non-glomerular hematuria].
- [Immunologic aspects of kidney transplantation].
- [Analgesic nephropathy in regions in Vojvodina].
- Some characteristics of renal injury in plasma Cell dyscrasias.
Procedures Preformed
- Joint Drainage
- Myofascial Trigger Point Injection
- Steroid Injection
- Trigger Point Injection
- View All
Conditions Treated
- Adhesive Capsulitis
- Amyloidosis
- Ankylosing Spondylitis
- Ankylosing Vertebral Hyperostosis
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Novi Sad Faculty of Medicine
Drug Facts
| NPI NUMBER | 1790772846 | |
| NPPES Provider LastName | LENERT | |
| NPPES Provider FirstName | PETAR | |
| NPPES Provider ZIPCode | 522421009 | |
| NPPES Provider State | IA | |
| Specialty Description | Rheumatology | |
| Total Claim Count | 1697.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 75.0 | |
| Percent Opioid Claims | 4.42 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1790772846 |
| Last Name Of The Provider | LENERT |
| First Name Of The Provider | PETAR |
| View All |
Similar Doctors
|
|
Dr. M P. Strottmann, MD |
|
|
Dr. Robert F. Ashman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John S. Cowdery, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott A. Vogelgesang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rebecca S. Tuetken, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Craig T. Morita, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Tyson P. Hagen, MD |
|
|
Dr. Jacob Ijdo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tamara L. Nelson, MD |
|
|
Dr. Bharat Kumar, MD |